{"DataElement":{"publicId":"2181260","version":"1","preferredName":"Common Toxicity Criteria Adverse Event Baseline Audiogram Grade","preferredDefinition":"in CTC category Auditory/Ear, assessment of the severity of a hearing adverse event using a graded scale for patients with or without baseline audiogram and enrolled in a monitoring program.","longName":"CTC_AE_BSL_AUDIOG_GD","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2195980","version":"1","preferredName":"Common Toxicity Criteria Adverse Event Baseline Audiogram","preferredDefinition":"information related to the CTC adverse event of baseline hearing.","longName":"CTC_AE_BSL_AUDIOGRAM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2480706","version":"1","preferredName":"Common Terminology Criteria for Adverse Events","preferredDefinition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","longName":"C49704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Common Terminology Criteria for Adverse Events","conceptCode":"C49704","definition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"133A63CA-49B0-49FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-07","modifiedBy":"ONEDATA","dateModified":"2006-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2207512","version":"1","preferredName":"Baseline Audiogram","preferredDefinition":"Baseline; an imaginary standard by which things are measured or compared.:specific test to measure the acuity of the sense of hearing to determine the thresholds of the lowest intensity levels at which an individual can hear a set of tones; frequencies between 125 and 8000 Hz are used to test air conduction thresholds and the frequencies between 250 and 4000 Hz are used to test bone conduction thresholds.","longName":"C25213:C0004286","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Baseline","conceptCode":"C25213","definition":"A starting point to which things may be compared.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Audiogram","conceptCode":"C0004286","definition":"specific test to measure the acuity of the sense of hearing to determine the thresholds of the lowest intensity levels at which an individual can hear a set of tones; frequencies between 125 and 8000 Hz are used to test air conduction thresholds and the frequencies between 250 and 4000 Hz are used to test bone conduction thresholds.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-2684-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDF51034-DF0E-3241-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-01-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-01-20","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2181259","version":"1","preferredName":"Common Toxicity Criteria Adverse Event Baseline Audiogram Grade","preferredDefinition":"in CTC category Auditory/Ear, assessment of the severity of a hearing adverse event using a graded scale for patients with or without baseline audiogram and enrolled in a monitoring program.","longName":"CTC_AE_BSL_AUDIOG_GD","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"NUMBER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"0","valueDescription":"None at all","ValueMeaning":{"publicId":"2574138","version":"1","preferredName":"None at all","longName":"2574138","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EEA7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CLOHNES","dateModified":"2022-08-12","changeDescription":null,"administrativeNotes":"8/12/22 added alt VM for Alliance cjl;","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D3B7E479-FBED-6543-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"PWEST","dateCreated":"2004-02-19","modifiedBy":"SBREXT","dateModified":"2007-06-22","deletedIndicator":"No"},{"value":"1","valueDescription":"Threshold shift or loss of 15-25 dB relative to baseline, averaged at 2 or more contiguous test frequencies in at least one ear; or subjective change in the absence of a Grade 1 threshold shift","ValueMeaning":{"publicId":"2568422","version":"1","preferredName":"Threshold shift or loss of 15-25 dB relative to baseline, averaged at 2 or more contiguous test frequencies in at least one ear; or subjective change in the absence of a Grade 1 threshold shift","longName":"2568422","preferredDefinition":"Threshold shift or loss of 15-25 dB relative to baseline, averaged at 2 or more contiguous test frequencies in at least one ear; or subjective change in the absence of a Grade 1 threshold shift","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D853-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-19","endDate":null,"createdBy":"PWEST","dateCreated":"2004-02-19","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D3B7E479-FBF0-6543-E034-0003BA12F5E7","beginDate":"2004-02-19","endDate":null,"createdBy":"PWEST","dateCreated":"2004-02-19","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"2","valueDescription":"Threshold shift or loss of >25-90 dB, averaged at 2 contiguous test frequencies in at least one ear","ValueMeaning":{"publicId":"2568423","version":"1","preferredName":"Threshold shift or loss of >25-90 dB, averaged at 2 contiguous test frequencies in at least one ear","longName":"2568423","preferredDefinition":"Threshold shift or loss of >25-90 dB, averaged at 2 contiguous test frequencies in at least one ear","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D854-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-19","endDate":null,"createdBy":"PWEST","dateCreated":"2004-02-19","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D3B7E479-FBF4-6543-E034-0003BA12F5E7","beginDate":"2004-02-19","endDate":null,"createdBy":"PWEST","dateCreated":"2004-02-19","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"3","valueDescription":"Adult only: Threshold shift of >25-90 dB, averaged at 3 contiguous test frequencies in at least one ear. Pediatric: Hearing loss sufficient to indicate therapeutic intervention, including hearing aids (e.g., >=20 dB bilateral HL in the speech frequencies;","ValueMeaning":{"publicId":"2568424","version":"1","preferredName":"Adult only: Threshold shift of >25-90 dB, averaged at 3 contiguous test frequencies in at least one ear. Pediatric: Hearing loss sufficient to indicate therapeutic intervention, including hearing aids (e.g., >=20 dB bilateral HL in the speech frequencies;","longName":"2568424","preferredDefinition":"Adult only: Threshold shift of >25-90 dB, averaged at 3 contiguous test frequencies in at least one ear. Pediatric: Hearing loss sufficient to indicate therapeutic intervention, including hearing aids (e.g., >=20 dB bilateral HL in the speech frequencies; >=30 dB unilateral HL; and requiring additional speech-language related services)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D855-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-19","endDate":null,"createdBy":"PWEST","dateCreated":"2004-02-19","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D3B7E479-FBF8-6543-E034-0003BA12F5E7","beginDate":"2004-02-19","endDate":null,"createdBy":"PWEST","dateCreated":"2004-02-19","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"4","valueDescription":"Adult only: Profound bilateral hearing loss (>90 dB). Pediatric: Audiologic indication for cochlear implant and requiring additional speech-language related services","ValueMeaning":{"publicId":"2568425","version":"1","preferredName":"Adult only: Profound bilateral hearing loss (>90 dB). Pediatric: Audiologic indication for cochlear implant and requiring additional speech-language related services","longName":"2568425","preferredDefinition":"Adult only: Profound bilateral hearing loss (>90 dB). Pediatric: Audiologic indication for cochlear implant and requiring additional speech-language related services","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D856-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-19","endDate":null,"createdBy":"PWEST","dateCreated":"2004-02-19","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D3B7E479-FBFC-6543-E034-0003BA12F5E7","beginDate":"2004-02-19","endDate":null,"createdBy":"PWEST","dateCreated":"2004-02-19","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2184299","version":"1","preferredName":"Grade","preferredDefinition":"Describes how closely a cancer resembles normal tissue of its same type, and the cancer's probable rate of growth","longName":"Grade","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Histologic Grade","conceptCode":"C18000","definition":"The degree of abnormality of cancer cells, a measure of differentiation, the extent to which cancer cells are similar in appearance and function to healthy cells of the same tissue type. The degree of differentiation often relates to the clinical behavior of the particular tumor. Based on the microscopic findings, tumor grade is commonly described by one of four degrees of severity. Histopathologic grade of a tumor may be used to plan treatment and estimate the future course, outcome, and overall prognosis of disease. Certain types of cancers, such as soft tissue sarcoma, primary brain tumors, lymphomas, and breast have special grading systems.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-1C87-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D3BC475B-307C-0650-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-02-19","endDate":null,"createdBy":"PWEST","dateCreated":"2004-02-19","modifiedBy":"REEVESD","dateModified":"2014-01-12","changeDescription":"created to meet criteria for CTCAE version 3.0","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2812032","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]},{"publicId":"2604617","version":"1","longName":"Submission and Reporting","context":"CTEP","ClassificationSchemeItems":[{"publicId":"10000132","version":"1","longName":"Common Terminology Criteria for Adverse Events v3.0","context":"CTEP"}]},{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[{"name":"CTCAE3_1310000_GRADE","type":"COG Form Element","context":"CTEP"}],"ReferenceDocuments":[{"name":"Source","type":"DATA_ELEMENT_SOURCE","description":"Data element and all values comply with Common Terminology Criteria for Adverse Events v3.0 (CTCAE)","url":"http://ctep.cancer.gov/reporting/ctc.html","context":"CTEP"},{"name":"CTC Adverse Event Hearing pat","type":"Preferred Question Text","description":"CTC Adverse Event Hearing patients with/without baseline audiogram and enrolled in a monitoring program Grade","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Hearing (monitoring program) Grade","url":null,"context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"D3B7ECCE-4624-6532-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-02-19","endDate":null,"createdBy":"PWEST","dateCreated":"2004-02-19","modifiedBy":"REEVESD","dateModified":"2011-04-15","changeDescription":"created to meet criteria for CTCAE version 3.0","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}